- Home
- FTRE vs QURE Comparison
FTRE vs QURE Comparison
Compare FTRE & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- QURE
- Stock Information
- Founded
- FTRE 1996
- QURE 1998
- Country
- FTRE United States
- QURE Netherlands
- Employees
- FTRE N/A
- QURE N/A
- Industry
- FTRE Medical Specialities
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- FTRE Health Care
- QURE Health Care
- Exchange
- FTRE Nasdaq
- QURE Nasdaq
- Market Cap
- FTRE 701.9M
- QURE 725.4M
- IPO Year
- FTRE N/A
- QURE 2007
- Fundamental
- Price
- FTRE $8.86
- QURE $15.55
- Analyst Decision
- FTRE Hold
- QURE Strong Buy
- Analyst Count
- FTRE 10
- QURE 10
- Target Price
- FTRE $14.00
- QURE $36.90
- AVG Volume (30 Days)
- FTRE 1.7M
- QURE 1.1M
- Earning Date
- FTRE 08-06-2025
- QURE 07-29-2025
- Dividend Yield
- FTRE N/A
- QURE N/A
- EPS Growth
- FTRE N/A
- QURE N/A
- EPS
- FTRE N/A
- QURE N/A
- Revenue
- FTRE $2,733,500,000.00
- QURE $14,337,000.00
- Revenue This Year
- FTRE N/A
- QURE N/A
- Revenue Next Year
- FTRE N/A
- QURE $278.91
- P/E Ratio
- FTRE N/A
- QURE N/A
- Revenue Growth
- FTRE N/A
- QURE N/A
- 52 Week Low
- FTRE $3.97
- QURE $4.45
- 52 Week High
- FTRE $25.28
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- FTRE 71.99
- QURE 57.39
- Support Level
- FTRE $7.40
- QURE $14.70
- Resistance Level
- FTRE $8.36
- QURE $16.43
- Average True Range (ATR)
- FTRE 0.68
- QURE 0.80
- MACD
- FTRE 0.10
- QURE 0.14
- Stochastic Oscillator
- FTRE 97.75
- QURE 70.56
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.